A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI (EGFRI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01763307|
Recruitment Status : Unknown
Verified December 2012 by Hadassah Medical Organization.
Recruitment status was: Not yet recruiting
First Posted : January 8, 2013
Last Update Posted : January 8, 2013
Vitamin K1 cream may prevent papulopustular rash induced by EGFRI given to metastatic colorectal cancer patients.
This study will prospectively accrue metastatic colorectal patients receiving EGFRI and treat with reconval cream half face versus placebo cream half face to study whether Vitamin k1 cream can prevent the typical skin eruption caused by EGFRI.
|Condition or disease||Intervention/treatment||Phase|
|Rash Due to Epidermal Growth Factor Receptor Inhibitors||Drug: RECONVAL CREAM Drug: PLACEBO||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment.|
|Study Start Date :||January 2013|
|Estimated Primary Completion Date :||January 2014|
|Estimated Study Completion Date :||December 2014|
Experimental: RECONVAL CREAM
half face treated with RECONVAL CREAM
Drug: RECONVAL CREAM
Placebo Comparator: PLACEBO
half face treated with PLACEBO cream
- Potential reduction in skin toxicity by Vitamin K1 cream in metastatic colorectal patients treated with EGFRI [ Time Frame: 12 weeks ]Reduction in numbers of papulo-pustular eruptions in the treatment fields compared to the placebo treated side. Changes in follicular eruptions, dryness/redness of skin estimated by the grading scale developed by the Multinational Association of Supportive Care in Cancer (MASCC) skin toxicity study group 4.0. Patients own experience of efficacy estimated by questionnaire.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01763307
|Contact: Hadas` Lemberg, PHD LLB||+972 2 firstname.lastname@example.org|
|Principal Investigator:||Sharon Merims, MD||Hadassah Medcial Organization|